For the millions of adults taking GLP-1 receptor agonists primarily for weight loss rather than diabetes management, a clinically important caveat is emerging: these drugs may quietly erode hip bone density faster than aging alone would predict. The finding matters most for the growing cohort of non-diabetic, postmenopausal women who represent a large share of current GLP-1 RA users.
This matched retrospective study from a single center enrolled 510 adults — 255 using semaglutide or tirzepatide for at least six months and 255 age-, sex-, BMI-, and diabetes-status-matched controls, each with paired DXA scans. The cohort was predominantly female (92%) with a mean age of 64 years. Over a median follow-up of 17 months, GLP-1 RA users achieved roughly 5% weight loss. Both groups experienced statistically significant declines in total hip (TH) and femoral neck (FN) bone mineral density. Critically, in participants without diabetes, the GLP-1 RA group lost more annualized TH bone density than controls (−1% vs. −0.6%, p = .04). Among those with diabetes, bone loss rates were comparable between groups. Weight loss magnitude correlated directly with bone loss at the hip (r = 0.32) and femoral neck (r = 0.17).
This study adds meaningful texture to an unsettled debate. Prior mechanistic work suggested GLP-1 receptor signaling on osteoblasts and osteoclasts might be bone-protective, yet the weight-loss-driven reduction in mechanical loading on the skeleton appears to offset any pharmacological benefit — particularly in non-diabetic users who may lack the compensatory metabolic changes seen in type 2 diabetes. The retrospective, single-center design and relatively short follow-up limit causal conclusions, and fracture incidence data were not reported. Still, for clinicians, the practical implication is clear: baseline DXA screening and ongoing bone density monitoring deserve routine consideration in non-diabetic adults initiating GLP-1 RA therapy, especially older women already at fracture risk. This finding is incremental but clinically actionable.